.Pharmacolibrary.Drugs.ATC.J.J05AR16 .Pharmacolibrary.Drugs.ATC.J.J05AR16| name: | LamivudineAndRaltegravir |
| ATC code: | J05AR16 | route: | oral |
| n-compartments | 1 |
Lamivudine and raltegravir is a fixed-dose combination antiretroviral medication used for the treatment of Human Immunodeficiency Virus (HIV) infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while raltegravir is an integrase inhibitor. This combination is currently approved and used for HIV treatment as part of antiretroviral therapy.
Estimated pharmacokinetic parameters for adult subjects, as no direct clinical PK studies for the fixed-dose combination have been published. Estimates are based on separate published parameters for each drug, assuming standard oral dosing in adults without renal or hepatic impairment.